Achira Labs

What Achira Labs does

Achira Labs Private Limited is an India-based point-of-care immunodiagnostics company founded in 2009 and headquartered in Bengaluru. It develops and commercializes diagnostic platforms that bring laboratory-grade quantitative results to clinic and point-of-care settings, targeting healthcare providers, diagnostic laboratories, fertility centers, and resource-limited health systems. The company operates three core product lines: μFluidix, a hydrogel-based multiplexed microfluidics platform delivering lab gold-standard results in under 35 minutes with panels for fertility, thyroid, and respiratory diagnostics; QuantALFA, a quantitative lateral flow assay reader system with proprietary test cassettes for Cystatin-C, CRP, and hs-CRP that delivers results in approximately 15-20 minutes with <3% coefficient of variation; and USelect, a magnetic bead-based sperm separation kit for assisted reproductive technology procedures. Underlying technology differentiators include proprietary gold nanoshell particles achieving a 100-fold sensitivity improvement over conventional lateral flow assays and a patented smartphone-based reader enabling quantitative readout on standard LFA platforms, complemented by a companion mobile application for wireless reader pairing, QR code scanning, and digital result logging.

The company's revenue model combines hardware sales of proprietary diagnostic readers and analyzers with recurring revenue from consumable test cassettes and panels, supported by quote-based institutional pricing. Go-to-market is direct enterprise sales targeting hospitals, clinics, and diagnostic laboratories through consultative selling, supplemented by digital presence via the company website with technical documentation, correlation charts, and lead-capture forms for demos, document requests, and partnership inquiries. The QuantALFA test kits have received CDSCO regulatory approval for the Indian in-vitro diagnostics market. The Gates Foundation provides grant funding supporting development of an HbA1c diabetes test and a Micronutrient Panel targeting resource-limited global health settings. The company employs 11-50 people and is led by co-founder and CEO Dr. Dhananjaya Dendukuri alongside co-founder and Director Suri Venkatchalam, with a seven-person-plus leadership team across R&D, lateral flow assay development, clinical studies, program management, biomanufacturing, business development, and operations, supported by four scientific and clinical advisors.

Name

Achira Labs

Legal name

Achira Labs Private Limited

Website

https://achiralabs.com

Company type

Private

Founded year

2009

Operating status

Operating

Headcount range

11–50 employees

Short description

Achira Labs is an India-based point-of-care immunodiagnostics company developing microfluidics (μFluidix), quantitative lateral flow (QuantALFA), and sperm separation (USelect) platforms that deliver lab-quality results to clinics, hospitals, fertility centers, and resource-limited health systems.

Ownership category

akta.pro rank

Product category

Point-of-Care Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN)

akta.pro secondary industries

Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers) (HLAHACAL), Liquid Handling & Laboratory Automation (Pipettes, Robots, Workstations) (HLAGAIAD)

Keywords

• Point-of-care diagnostics
• Lateral flow assays
• Microfluidic diagnostics
• Rapid immunoassay testing
• Quantitative diagnostic readers

Headquarters

HQ city

Bangalore

HQ country

India

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Revenue model

1. Diagnostic Hardware Sales: Sale of proprietary diagnostic readers and analyzers including μFluidix microfluidics analyzer and QuantALFA lateral flow readers.
2. Diagnostic Test Kits and Panels: Recurring revenue from consumable test cassettes and panels including μFluidix panels (Fertility, Thyroid, Respiratory), QuantALFA tests (Cystatin C, CRP, hs-CRP), and USelect sperm separation kits.
3. Pipeline Product Development: Future revenue streams from products in development pipeline including HbA1c, Dengue NS1, TSH, PCT, Micronutrient Panel, Anemia Panel, and Tropical Fever Panel.

Pricing tiers

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Core offering

Achira Labs develops and manufactures point-of-care diagnostic platforms and consumable test kits. Its core offerings include the μFluidix hydrogel-based multiplexed microfluidics platform and the QuantALFA quantitative lateral flow assay reader with proprietary test cassettes (Cystatin C, CRP, hs-CRP), delivering lab-quality results in 15-35 minutes. The company also sells USelect, a magnetic bead-based sperm separation kit for assisted reproductive technology (ART) procedures.

Product overview

Achira Labs offers a multi-platform point-of-care diagnostics portfolio centered on three core product lines: μFluidix (a high-sensitivity, hydrogel-based multiplexed platform delivering lab gold-standard results in under 35 minutes with test panels for fertility, thyroid, and respiratory conditions), QuantALFA (a quantitative lateral flow assay platform comprising a portable reader device and proprietary test cassettes including Cystatin-C, CRP, and hs-CRP, with results in under 20 minutes), and USelect (a magnetic bead-based sperm separation kit for assisted reproductive technology). The platforms share a focus on bringing quantitative, lab-quality diagnostics to point-of-care settings, with the QuantALFA ecosystem including a companion mobile app for wireless reader pairing and result management. Pipeline products under development include additional biomarkers such as HbA1c, Dengue NS1, TSH, PCT, and panels for micronutrients, anemia, and tropical fever.

Differentiator

Problem solved

Functional benefit

Brands

• μFluidix: High sensitivity, hydrogel based multiplexed platform delivering lab gold standard results in under 35 min.
• QuantALFA
• USelect

Products and services

• μFluidix

Quantifiable outcome

• Results in under 35 minutes for μFluidix panels and 15-20 minutes for QuantALFA tests
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators2 records

Recent moves5 records

Expansion highlights6 records

Direct peers

• Mylab Discovery Solutions: India-based IVD manufacturer offering molecular diagnostics, rapid antigen tests, and POC platforms. Directly comparable to Achira in geography, customer base (Indian clinics/hospitals), and POC diagnostic focus, with overlapping respiratory pathogen and infectious disease menus.

Broad incumbents

• Abbott Point of Care: Operates the i-STAT and Alinity POC diagnostic platforms with broad menus including cardiac, inflammatory (CRP), and renal markers. Comparable in POC clinical chemistry/immunoassay category and target end-users (clinics, hospitals), though Abbott is a global incumbent with vastly broader portfolio and reach.
• QuidelOrtho: Sofia and Triage product lines deliver quantitative rapid diagnostics for infectious disease and cardiovascular markers at POC. Comparable in lateral-flow-based quantitative POC diagnostics and clinical segment focus; competes head-on in respiratory and CRP testing where Achira's μFluidix and QuantALFA also play.
• Becton Dickinson (BD): BD Veritor Plus and FACSPresto systems offer quantitative POC diagnostics for infectious disease, women's health, and chronic disease. Comparable in POC lateral-flow quantitative testing and clinical channel; a key global competitor for both CRP/hs-CRP and respiratory panel placements.
• Roche Diagnostics: Cobas and Elecsys platforms dominate central lab clinical chemistry and immunoassay, with reference methods (e.g., Cobas CRP) used to validate Achira's QuantALFA correlation. Comparable in immunoassay/clinical chemistry menu and target end-users; represents both a reference benchmark and a long-term competitive threat if Roche extends into POC.
• Siemens Healthineers: Atellica NEPH 630 and CLINITEK Status platforms are used as reference methods in Achira's correlation data. Comparable in clinical chemistry/immunoassay menu; sets the accuracy bar Achira must meet for hospital adoption and is a major installed-base competitor in renal (Cystatin-C) and inflammatory (CRP) testing.
• Cepheid (Danaher): GeneXpert molecular POC systems deliver quantitative results for infectious disease, women's health, and oncology in decentralized settings. Comparable in POC quantitative diagnostics for respiratory pathogens (Influenza A/B, RSV, SARS-CoV-2) where μFluidix Respiratory Panel also competes.

Regional players

• J Mitra & Co: India-based IVD manufacturer with a broad lateral-flow and ELISA product portfolio spanning infectious disease, fertility, thyroid, and cardiac markers. Comparable to Achira in geography (Indian market) and POC diagnostics category, with overlapping fertility and thyroid menu items.
• Trivitron Healthcare: India-headquartered medical technology company with IVD, imaging, and newborn screening portfolios. Comparable in India-centric IVD manufacturing and clinical-channel sales; competes in immunoassay and clinical chemistry categories overlapping Achira's panels.

Emerging players

• Hemex Health: US-based POC diagnostics startup developing affordable tests for malaria, sickle cell, and infectious diseases targeting emerging markets. Comparable in resource-limited POC mission, microfluidics/cartridge-based delivery, and global-health funding model (similar to Achira's Gates-backed HbA1c work).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/in/raghavendra-katti-28390b1a
• Xx.com/achiradx

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Achira Labs